Allogeneic Transplantation
Multiple Myeloma Trials
COMIRB: 23-0376
(CaMMouflage) A Phase I Multicenter, Open-Label Study of CB011, a CRISPR-Edited Allogenic, Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
PI: Dan Sherbenou
Eligibility: Ages ≥ 18; diagnosed MM and evidence of PD based on IMWG criteria; ECOG of ≤1
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.